接受曲妥珠单抗德鲁昔单抗治疗的转移性扩增非小细胞肺癌。
Metastatic -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.
作者信息
Yun Karen M, Bazhenova Lyudmila
机构信息
Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, California, USA
Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, California, USA.
出版信息
BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.
Abstract
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic -mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with -amplified NSCLC. Here, we present the first reported case of metastatic -amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
摘要
人表皮生长因子受体2（HER2）改变可表现为基因突变、基因扩增或蛋白过表达。DESTINY-Lung01和DESTINY-Lung02试验证明了曲妥珠单抗德鲁昔康在不可切除或转移性HER2突变非小细胞肺癌（NSCLC）患者后续治疗中的疗效。曲妥珠单抗德鲁昔康尚未在特定的HER2扩增NSCLC患者中进行研究。在此，我们报告首例接受曲妥珠单抗德鲁昔康治疗且对治疗有持久反应的转移性HER2扩增NSCLC病例。
相似文献
1
Metastatic -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.接受曲妥珠单抗德鲁昔单抗治疗的转移性扩增非小细胞肺癌。
BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.
2
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.
3
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
4
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.FDA 批准摘要：fam-trastuzumab deruxtecan-nxki 用于不可切除或转移性非小细胞肺癌伴激活的 HER2 突变。
Oncologist. 2024 Aug 5;29(8):667-671. doi: 10.1093/oncolo/oyae151.
5
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer.曲妥珠单抗德鲁替康作为HER2突变型晚期非小细胞肺癌二线治疗的成本效益
Hum Vaccin Immunother. 2025 Dec;21(1):2468070. doi: 10.1080/21645515.2025.2468070. Epub 2025 Feb 24.
6
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.曲妥珠单抗 deruxtecan 治疗 HER2 突变型非小细胞肺癌：DESTINY-Lung01 研究的通俗易懂总结。
Future Oncol. 2024;20(27):1961-1971. doi: 10.1080/14796694.2024.2355724. Epub 2024 Jul 16.
7
Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.针对 HER2 可能超越 NSCLC 的化疗和免疫治疗。
Cancer Discov. 2021 Dec 1;11(12):OF3. doi: 10.1158/2159-8290.CD-NB2021-0394.
8
FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.FDA 批准 T-DXd 用于治疗 HER2 突变型 NSCLC。
Cancer Discov. 2022 Oct 5;12(10):2224. doi: 10.1158/2159-8290.CD-NB2022-0053.
9
[Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy].[曲妥珠单抗-德曲妥珠单抗单药治疗经铂类化疗联合或不联合免疫治疗的HER2激活型晚期非小细胞肺癌]
Bull Cancer. 2024 Jun;111(6):539-540. doi: 10.1016/j.bulcan.2024.01.011. Epub 2024 Mar 28.
10
Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.曲妥珠单抗德鲁替康在HER2突变型非小细胞肺癌中显示出持久的活性。
Cancer. 2022 Mar 1;128(5):938. doi: 10.1002/cncr.34102.
引用本文的文献
1
A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors.曲妥珠单抗德鲁替康诱导实体瘤患者发生间质性肺疾病/肺炎的机制、发生率及管理的系统评价
Drug Des Devel Ther. 2025 Mar 8;19:1655-1668. doi: 10.2147/DDDT.S508773. eCollection 2025.
本文引用的文献
1
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
2
Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.针对非小细胞肺癌中HER2改变的综合综述
JCO Precis Oncol. 2020 Nov;4:411-425. doi: 10.1200/PO.19.00333.
3
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
4
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.针对非小细胞肺癌（NSCLC）中的 HER2：一线希望？HER2 改变 NSCLC 的治疗策略更新综述。
ESMO Open. 2021 Oct;6(5):100260. doi: 10.1016/j.esmoop.2021.100260. Epub 2021 Aug 31.
5
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.晚期非小细胞肺癌的靶向治疗：当前进展与未来趋势。
J Hematol Oncol. 2021 Jul 8;14(1):108. doi: 10.1186/s13045-021-01121-2.
6
Crizotinib in Patients With MET-Amplified NSCLC.克唑替尼治疗 MET 扩增型 NSCLC 患者的疗效。
J Thorac Oncol. 2021 Jun;16(6):1017-1029. doi: 10.1016/j.jtho.2021.02.010. Epub 2021 Mar 4.
7
Genomic alterations of ERBB receptors in cancer: clinical implications.癌症中ERBB受体的基因组改变：临床意义
Oncotarget. 2017 Nov 30;8(69):114371-114392. doi: 10.18632/oncotarget.22825. eCollection 2017 Dec 26.
8
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.肺腺癌中的HER2突变：来自肺癌突变联盟的报告。
Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.
9
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.肺腺癌中HER2改变的频率及临床影响
PLoS One. 2017 Feb 1;12(2):e0171280. doi: 10.1371/journal.pone.0171280. eCollection 2017.
10
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.HER2基因扩增和HER2突变是肺癌中不同的分子靶点。
J Thorac Oncol. 2016 Mar;11(3):414-9. doi: 10.1016/j.jtho.2015.10.025. Epub 2015 Dec 24.
Zotero 插件